Breaking News

ReiThera Expands Large-scale Viral Vector Production Capabilities

New 1,500 square meter facility granted operational authorization from AIFA, the Italian Medicines Agency, to enable production scales of up to 3,000 liters.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ReiThera, a biotech company dedicated to the development of new technologies, GMP production and the clinical translation of genetic vaccines and products for advanced therapies, has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area at its pharmaceutical facility at the Castel Romano Technopole, for the large-scale production of viral vectors for vaccines and gene therapy.  Designed to meet the growing global demand for viral vector pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters